Medical Condition News

RSS

Tolerx presents preclinical data on TRX518 anti-GITR immunotherapy for cancer

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.

28 Jun 2010

Experts to discuss latest trends in treatments, diagnostic techniques for managing HCC

Today, world renowned experts have assembled in Dubrovnik, Croatia to discuss the latest trends in treatment and cutting edge research in diagnostic techniques that will shape the future management of hepatocellular carcinoma - the third most common cause of cancer-related death globally, and a leading cause of death among patients with liver cirrhosis.

28 Jun 2010

In-school education programs can reduce obesity, other risk factors for type 2 diabetes: HEALTHY

Healthier cafeteria choices, longer and more intense periods of physical activity and robust in-school education programs can lower rates of obesity and other risk factors for type 2 diabetes, according to a national study called HEALTHY.

28 Jun 2010

Cardiac MRI helps avoid hospital admissions for chest pain patients

A new study done by researchers at Wake Forest University Baptist Medical Center indicates that chest pain may no longer have to mean a hospital stay - there is another option for diagnosing heart-related chest pain that costs less and, in some cases, allows the patient to return home the same day.

28 Jun 2010

Elevated blood levels of HDL can be harmful to women with type 1 diabetes: Study

Elevated blood levels of high-density lipoprotein or "good" cholesterol, typically thought to protect against heart disease, may do the opposite in women with type 1 diabetes, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 70th Scientific Sessions of the American Diabetes Association.

28 Jun 2010

Phase 2 proof-of-concept data for Novo Nordisk's degludec presented at ADA 2010

Novo Nordisk today presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association.

28 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.

28 Jun 2010

New center opens for vets with traumatic brain injuries and psychological issues

"The $65 million medical center, which opened Thursday, is devoted exclusively to helping members of the military who suffer from traumatic brain injuries, PTSD and other psychological issues. Its opening comes on the heels of a flurry of congressional criticism and reports claiming that soldiers with traumatic brain injuries often do not have their conditions diagnosed and are forced to wade through the vast bureaucracy of the Defense Centers of Excellence for Psychological Help and Traumatic Brain Injury, which is charged with their treatment."

28 Jun 2010

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.

28 Jun 2010

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced data on ZGN-201, a prototype methionine aminopeptidase 2 inhibitor, for the treatment of obesity. Preclinical studies demonstrate MetAP2 inhibition eliminates excess body weight through the regulation of fat metabolism and food intake, and normalizes glucose tolerance in animal models.

28 Jun 2010

National Intrepid Center of Excellence to treat veterans with traumatic brain injury

The U.S. Department of Defense and the Intrepid Fallen Heroes Fund on June 24 officially dedicated the National Intrepid Center of Excellence, a new 72,000-square-foot medical facility in Bethesda, Md., dedicated to researching, diagnosing and treating traumatic brain injury in U.S. military personnel.

28 Jun 2010

Researchers discover genetic links to kidney failure, diabetic kidney disease

Researchers at the Translational Genomics Research Institute will make two presentations at this week's 70th Scientific Sessions of the American Diabetes Association, June 25-29, in Orlando, Florida.

28 Jun 2010

VPRIV receives positive opinion from CHMP for treatment of type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the marketing authorisation for VPRIV (velaglucerase alfa), the company's enzyme replacement therapy for the treatment of type 1 Gaucher disease.

28 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

Consuming omega-3 fatty acids may not lower heart disease risk for women with type 1 diabetes: Study

Consuming higher amounts of omega-3 fatty acids does not appear to lower heart disease risk for women with type 1 diabetes, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 70th Scientific Sessions of the American Diabetes Association.

28 Jun 2010

Mass. Legislature denies requests to trim municipal health benefits; N.Y. ordered to transfer people with mental Illness out of institutional group homes

"The state's public employee unions won a major victory this week when the Legislature abandoned efforts to allow cities and towns to trim generous health care benefits enjoyed by thousands of municipal employees, retirees, and elected officials. The decision by lawmakers not to address the issue in next year's budget means the Legislature will almost certainly not act on it this year, setting the stage for mayors and other municipal officials to take their case directly to voters in a ballot initiative for 2012" (Murphy, 6/25).

28 Jun 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Late-breaking Novo Nordisk extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose than Januvia plus metformin at 52 weeks.

28 Jun 2010

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.

28 Jun 2010

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Human Genome Sciences, Inc. today announced the presentation of additional results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Vancouver at the 9th International Congress on Systemic Lupus Erythematosus on Friday and Saturday, June 25-26.

28 Jun 2010

Medical Condition News

Tolerx presents preclinical data on TRX518 anti-GITR immunotherapy for cancer

Experts to discuss latest trends in treatments, diagnostic techniques for managing HCC

In-school education programs can reduce obesity, other risk factors for type 2 diabetes: HEALTHY

Cardiac MRI helps avoid hospital admissions for chest pain patients

Elevated blood levels of HDL can be harmful to women with type 1 diabetes: Study

Phase 2 proof-of-concept data for Novo Nordisk's degludec presented at ADA 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

New center opens for vets with traumatic brain injuries and psychological issues

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

National Intrepid Center of Excellence to treat veterans with traumatic brain injury

Researchers discover genetic links to kidney failure, diabetic kidney disease

VPRIV receives positive opinion from CHMP for treatment of type 1 Gaucher disease

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

Consuming omega-3 fatty acids may not lower heart disease risk for women with type 1 diabetes: Study

Mass. Legislature denies requests to trim municipal health benefits; N.Y. ordered to transfer people with mental Illness out of institutional group homes

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News